


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (currently amended) A quinazoline derivative having the following formula (1) or a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

R<sup>1</sup> represents (a) hydroxyl group, (b) an amino group, (c) a C<sub>1</sub> to C<sub>4</sub> lower alkylamino group which may be substituted with a COOH group, (d) a C<sub>7</sub> and C<sub>10</sub> lower aralkylamino group which may be substituted with a COOH group, (e) an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a COOH group, (f) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (g) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (h) an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a COOH group, (i) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (j) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a

COOH group, (k) a  $C_1$  to  $C_4$  lower alkyl group substituted with a COOH group, or (l) a  $C_2$  to  $C_4$  lower alkenyl group which may be substituted with a COOH group;

$R^2$  and  $R^3$  may be the same or different and represent (a) a hydrogen atom, (b) (a) a  $C_1$  to  $C_4$  lower alkyl group which may be substituted with a COOH group, a halogen atom, a  $C_1$  to  $C_4$  lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) (b) a halogen atom, (d) (c) a hydroxyl group, (e) (d) a  $C_1$  to  $C_4$  lower alkoxy group, (f) (e) an amino group, (g) (f) a  $C_1$  to  $C_4$  lower alkylamino group which may be substituted with a COOH group, a halogen atom or a  $C_1$  to  $C_4$  lower alkoxy group, (h) (g) a  $C_7$  to  $C_{12}$  aralkylamino group which may be substituted with a COOH group, a halogen atom or a  $C_1$  to  $C_4$  lower alkoxy group, (i) (h) an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid which may be substituted with a COOH group, (j) (i) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) (j) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) (k) an amino group sulfonylated with a  $C_1$  to  $C_4$  lower alkanesulfonic acid which may be substituted with a COOH group, (m) (l) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) (m) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) (n) a COOH group or

$R^3$  represents (a) a hydrogen atom, (b) a  $C_1$  to  $C_4$  lower alkyl group which may be substituted with a COOH group, a halogen atom, a  $C_1$  to  $C_4$  lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) a halogen atom, (d) a

hydroxyl group, (e) a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, (f) an amino group, (g) a C<sub>1</sub> to C<sub>4</sub> lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, (h) a C<sub>7</sub> to C<sub>12</sub> aralkylamino group which may be substituted with a COOH group, a halogen atom or a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, (i) an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or

when the ring A is benzene ring, R<sup>1</sup> and R<sup>2</sup> may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and R<sup>3</sup> is the same as defined above; and

X represents (a) a hydrogen atom, (b) a C<sub>1</sub> to C<sub>4</sub> lower alkyl group, (c) a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, ~~(e)~~ (f) an amino group, or (g) a nitro group, ~~with the proviso that, when A is a benzene ring and R<sup>1</sup> is an amino group, R<sup>2</sup> and R<sup>3</sup> are not a hydrogen atom at the same time.~~

2. (previously presented) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1),  $R^1$  is a hydroxyl group, an amino group, a  $C_1$  to  $C_4$  lower alkylamino group substituted with a COOH group, or an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid substituted with a COOH group.

3. (currently amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1),  $R^2$  is a COOH group ~~or a hydrogen atom~~.

4. (previously presented) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein  $R^3$  in the formula (I) is a hydrogen atom.

5. (previously presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier therefor.

6. (currently amended) A chymase inhibitor having as an effective ingredient a quinazoline derivative or its pharmaceutically acceptable salt according to claim 1, and a pharmaceutically acceptable carrier therefor.

7-13. (canceled)

14. (previously presented) A method for treatment of allergic diseases or rheumatic diseases comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

15. (previously presented) A method for treatment of bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriosis or rheumatoid arthritis comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

16. (previously presented) A method for treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Angiotensin II production comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

17. (previously presented) A method for treatment of cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory diseases, revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including cardiac infarction, angioendothelia or vascular disorders accompanying arterialization and atheroma comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

18-19. (canceled)


20. (previously presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 2, and a pharmaceutically acceptable carrier therefor.

21. (previously presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 3, and a pharmaceutically acceptable carrier therefor.

22. (previously presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 4, and a pharmaceutically acceptable carrier therefor.

23-25. (canceled)

26. (currently amended) A quinazoline derivative having the following formula (1) and a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

R<sup>1</sup> represents (a) hydroxyl group, (b) ~~an amino group~~, (c) a C<sub>1</sub> to C<sub>4</sub> lower alkylamino group which may be substituted with a COOH group, ~~(d)~~ (c) a C<sub>7</sub> and C<sub>10</sub> lower aralkylamino group which may be substituted with a COOH group, ~~(e)~~ (d) an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a COOH group, (e) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, ~~(g)~~ (f) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, ~~(h)~~ (g) an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid

which may be substituted with a COOH group, (i) (h) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (j) (i) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, (k) (j) a C<sub>1</sub> to C<sub>4</sub> lower alkyl group substituted with a COOH group, or (l) (k) a C<sub>2</sub> to C<sub>4</sub> lower alkenyl group which may be substituted with a COOH group;

R<sup>2</sup> and R<sup>3</sup> may be the same or different and represent (a) a hydrogen atom, (b) a C<sub>1</sub> to C<sub>4</sub> lower alkyl group which may be substituted with a COOH group, a halogen atom, a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) a halogen atom, (d) a hydroxyl group, (e) a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, (f) an amino group, (g) a C<sub>1</sub> to C<sub>4</sub> lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, (h) a C<sub>7</sub> to C<sub>12</sub> aralkylamino group which may be substituted with a COOH group, a halogen atom or a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, (i) an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or



when the ring A is benzene ring,  $R^1$  and  $R^2$  may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and  $R^3$  is the same as defined above; and

X represents (a) a hydrogen atom, (b) a  $C_1$  to  $C_4$  lower alkyl group, (c) a  $C_1$  to  $C_4$  lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, ~~(e)~~ (f) an amino group, or (g) a nitro group, ~~with the proviso that, when A is a benzene ring and  $R^1$  is an amino group,  $R^2$  and  $R^3$  are not a hydrogen atom at the same time,~~

~~wherein when A is a benzene ring and~~

~~$R^1$  represents an amino group,~~

~~$R^2$  and  $R^3$  are different and represent a hydrogen atom, an unsubstituted or a substituted  $C_1$  to  $C_4$  lower alkyl group which may be substituted with a COOH group, a  $C_1$  to  $C_4$  lower alkoxy group or a COOH group,~~

~~or~~

~~$R^2$  and  $R^3$  each represent a hydrogen atom.~~

27-28. (canceled)

29. (currently amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 26 1, wherein said compound is selected from the group consisting of

3-(3-amino-4-chlorobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione,

3-(4-amino-3,5-dichlorobenzenesulfonyl)-7-chloro-2,4(1H,3H)-  
quinazolinedione,  
3-(3-amino-4-methylbenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione,  
4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,  
4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid  
monosodium salt,  
3-(3-amino-4-methoxybenzenesulfonyl)-7-chloro-2,4(1H,3H)-  
quinazolinedione,  
5-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,  
4-[(7-methoxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,  
4-[(7-hydroxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid and  
4-[(6-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid.

30-31. (canceled)

32. (new) A pharmaceutical composition comprising as an effective  
ingredient a pharmaceutically effective amount of a quinazoline derivative or a  
pharmaceutically acceptable salt thereof according to claim 26 and a  
pharmaceutically acceptable carrier therefore.

33. (new) A chymase inhibitor having as an effective ingredient a quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 26 and a pharmaceutically acceptable carrier therefore.